ST. LOUIS, April 28, 2026, 10:59 CDT
Centene Corp bumped up its 2026 profit outlook Tuesday, following a first-quarter earnings beat that signaled tighter reins on medical expenses. Shares surged more than 6% in early trade, according to Reuters.
Investors, already nervous after more than two years of squeezed margins, have been hunting for evidence that managed-care firms can rein in care costs. Centene’s updated outlook lands just after larger rivals UnitedHealth and Elevance also bumped up their forecasts, sparking a modest relief trade for the sector.
Centene bumped up its 2026 adjusted diluted EPS floor to more than $3.40, up from the earlier mark of over $3.00. Revenue guidance for the full year now lands between $187.5 billion and $191.5 billion, compared with the old range of $186.5 billion to $190.5 billion.
Centene, based in St. Louis, posted first-quarter revenue of $49.94 billion. Adjusted diluted EPS came in at $3.37, with GAAP diluted EPS at $3.11. The health benefits ratio (HBR)—which tracks the proportion of premiums used for medical care—landed at 87.3%, slipping from 87.5% last year and beating the 89.42% analysts were looking for, according to Reuters.
Chief Executive Sarah M. London pointed to ongoing progress in margin recovery and highlighted improvements across Centene’s core operations. The latest quarter, she said, set Centene up to raise its full-year adjusted EPS outlook. London also reiterated confidence in the company’s long-term earnings strength.
Results landed ahead of expectations in most areas, though some pockets fell short. Medicaid premium and service revenue climbed 6% to $23.6 billion; Medicare jumped 18%, hitting $10.3 billion. But commercial revenue declined 6% to $9.6 billion, as lower Marketplace membership offset gains elsewhere.
Centene credits higher Medicaid rates, tighter rein on medical costs, and a mild flu season for the improved numbers. In Medicare, results came in strong too—both Medicare Advantage and its prescription-drug business outperformed, according to the company.
J.P. Morgan’s John Stansel described the result as “a positive start to the year,” though he flagged a handful of checkpoints coming in the next two quarters that could still influence Centene’s 2026 guidance. That kind of caution tracks with the company’s position: Centene holds more exposure than most rivals to government-backed Medicaid and Affordable Care Act Marketplace plans—areas where shifts in policy or membership can change the outlook fast. Reuters
Marketplace is where Centene faces the bulk of its risk. The company pointed to higher acuity for Silver-tier Obamacare members, nudging commercial costs just past projections this quarter. Risk adjustment—intended to balance out costs for insurers with sicker pools—could offer some relief. Still, Centene isn’t baking a full offset into its updated outlook.
Chief Financial Officer Andrew Asher cautioned analysts against simply projecting first-quarter results forward. According to Asher, the company expects a sequential earnings decline in the second quarter, a near break-even performance for the third, and a loss in the fourth—typical of the firm’s seasonal patterns.
Centene wrapped up the quarter with a more streamlined balance sheet. Operating cash flow hit $4.4 billion, and the company tapped money from a receivables sale to buy back $1.0 billion of senior notes maturing in 2027. As of March 31, total debt was reported at $16.4 billion.
At this stage, it’s straightforward: costs improved, guidance ticked higher, and shares responded. Tougher questions loom, though. Centene still needs more Marketplace risk adjustment data, and Medicaid cost trends will hit their real test as the year moves into its more challenging stretch.
